Telmisartan and Hydrochlorothiazide

Name: Telmisartan and Hydrochlorothiazide

Commonly used brand name(s)

In the U.S.

  • Micardis HCT

Available Dosage Forms:

  • Tablet

Therapeutic Class: Angiotensin II Receptor Antagonist/Thiazide Combination

Pharmacologic Class: Angiotensin II Receptor Antagonist

Chemical Class: Thiazide

How do I store and/or throw out Telmisartan and Hydrochlorothiazide?

  • Store in the original container at room temperature.
  • Store in a dry place. Do not store in a bathroom.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Check with your pharmacist about how to throw out unused drugs.

Telmisartan and Hydrochlorothiazide - Clinical Pharmacology

Mechanism of Action

Telmisartan and Hydrochlorothiazide Tablets

Telmisartan and Hydrochlorothiazide tablets are a combination of two drugs with antihypertensive properties: a thiazide diuretic, hydrochlorothiazide, and an angiotensin II receptor blocker (ARB), telmisartan.

Telmisartan

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.

There is also an AT2 receptor found in many tissues, but AT2 is not known to be associated with cardiovascular homeostasis. Telmisartan has much greater affinity (>3,000-fold) for the AT1 receptor than for the AT2 receptor.

Telmisartan does not inhibit ACE (kininase II) nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure.

Hydrochlorothiazide

Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium salt and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so co-administration of an ARB tends to reverse the potassium loss associated with these diuretics. The mechanism of the antihypertensive effect of thiazides is not fully understood.

Pharmacodynamics

Telmisartan

In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by approximately 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours.

Plasma concentration of angiotensin II and plasma renin activity increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients. The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium) or in metabolic function (including serum levels of cholesterol, triglycerides, HDL, LDL, glucose, or uric acid).

The antihypertensive effects of telmisartan have been studied in six placebo-controlled clinical trials including a total of 1773 patients with mild to moderate hypertension (diastolic blood pressure of 95 to 114 mmHg), 1031 of whom were treated with telmisartan. Following once-daily administration of telmisartan, the magnitude of blood pressure reduction from baseline after placebo subtraction was approximately (SBP/DBP) 6 to 8/6 mmHg for 20 mg, 9 to 13/6 to 8 mmHg for 40 mg, and 12 to 13/7 to 8 mmHg for 80 mg. Larger doses (up to 160 mg) did not appear to cause a further decrease in blood pressure.

The onset of antihypertensive activity occurs within 3 hours, with a maximal reduction by approximately 4 weeks. At doses of 20, 40, and 80 mg, the antihypertensive effect of once-daily administration of telmisartan was maintained for the full 24-hour dose interval.

In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance.

Hydrochlorothiazide

After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours, and lasts approximately 6 to 12 hours.

Drug Interactions

Hydrochlorothiazide

Alcohol, barbiturates, or narcotics: Potentiation of orthostatic hypotension may occur.

Skeletal muscle relaxants: Possible increased responsiveness to muscle relaxants such as curare derivatives.

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia.

Pressor amines (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use.

Pharmacokinetics

Telmisartan

Absorption:

Following oral administration, peak concentrations (Cmax) of telmisartan are reached in 0.5 to 1 hour after dosing.  Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of approximately 6% with 40 mg and approximately 20% after a 160 mg dose Telmisartan and Hydrochlorothiazide tablets can be administered with or without food.  The absolute bioavailability of telmisartan is dose dependent.  At 40 and 160 mg the bioavailability was 42% and 58%, respectively. The pharmacokinetics of telmisartan with orally administered telmisartan are nonlinear over the dose range 20 to 160 mg, with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses. Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours. Trough plasma concentrations of telmisartan with once-daily dosing are approximately 10% to 25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2.0 upon repeated once-daily dosing.

Distribution:

Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α1 -acid glycoprotein.  Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters, indicating additional tissue binding.

Metabolism:

Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.

Elimination:

Following either intravenous or oral administration of 14C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).

Total plasma clearance of telmisartan is >800 mL/min. Terminal half-life and total clearance appear to be independent of dose.

Hydrochlorothiazide

Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours. At least 61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Specific Populations

Telmisartan

Renal Insufficiency: Telmisartan is not removed from blood by hemofiltration [see Warnings and Precautions (5.3), and Use in Specific Populations (8.7)].

Hepatic Insufficiency: In patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% [see Use in Specific Populations (8.6)].

Gender: Plasma concentrations of telmisartan are generally 2 to 3 times higher in females than in males.  In clinical trials, however, no significant increases in blood pressure response or in the incidence of orthostatic hypotension were found in women.  No dosage adjustment is necessary.

Geriatric Patients: The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years of age.

Drug Interaction Studies

Telmisartan

Ramipril: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. In contrast, Cmax and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen.  Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.  Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.

Clinical Studies

Telmisartan and Hydrochlorothiazide

In controlled clinical trials with more than 2500 hypertensive patients, 1017 patients were exposed to telmisartan (20 mg to 160 mg) and concomitant hydrochlorothiazide (6.25 mg to 25 mg).  These trials included one factorial trial (Study 1) with combinations of telmisartan (20 mg, 40 mg, 80 mg, 160 mg, or placebo) and hydrochlorothiazide (6.25 mg, 12.5 mg, 25 mg, and placebo). The factorial trial randomized 818 patients, including 493 (60%) males; 596 (73%) Non-Black and 222 (27%) Blacks; and 143 (18%) ≥65 years of age (median age was 53 years old).  The mean supine blood pressure at baseline for the total population was 154/101 mmHg.

The combination of Telmisartan and Hydrochlorothiazide resulted in additive placebo-adjusted decreases in systolic and diastolic blood pressures at trough of 16 to 21/9 to 11 mmHg for doses between 40 mg/12.5 mg and 80 mg/25 mg, compared with 9 to 13/7 to 8 mmHg for telmisartan 40 mg to 80 mg monotherapy and 4/4 mmHg for hydrochlorothiazide 12.5 mg monotherapy. The antihypertensive effect was independent of age or gender.

There was essentially no change in heart rate in patients treated with the combination of Telmisartan and Hydrochlorothiazide in the placebo-controlled trial.

Four other studies of hypertensive patients of at least six months' duration allowed add-on of hydrochlorothiazide for patients who either were not adequately controlled on the randomized telmisartan monotherapy dose or had not achieved adequate blood pressure response after completing the up-titration of telmisartan.  In active-controlled studies, the addition of 12.5 mg hydrochlorothiazide to titrated doses of telmisartan in patients who did not achieve or maintain adequate response with telmisartan monotherapy further reduced systolic and diastolic blood pressures.

Package label.principal display panel

Telmisartan and Hydrochlorothiazide Tablets, USP 40 mg / 12.5 mg

Telmisartan and Hydrochlorothiazide Tablets, USP 80 mg / 12.5 mg

Telmisartan and Hydrochlorothiazide Tablets, USP 80 mg / 25 mg

Telmisartan and Hydrochlorothiazide Tablets, USP 40 mg / 12.5 mg (30 Unit dose Tablets)

Telmisartan and Hydrochlorothiazide Tablets, USP 80 mg / 12.5 mg (30 Unit dose Tablets)

Telmisartan and Hydrochlorothiazide Tablets, USP 80 mg / 25 mg (30 Unit dose Tablets)

TELMISARTAN AND HYDROCHLORTHIAZIDE 
telmisartan and hydrochlorthiazide tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:13668-159
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
TELMISARTAN (TELMISARTAN) TELMISARTAN 40 mg
HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) HYDROCHLOROTHIAZIDE 12.5 mg
Inactive Ingredients
Ingredient Name Strength
FERRIC OXIDE YELLOW  
HYPROMELLOSE 2910 (3 MPA.S)  
LACTOSE MONOHYDRATE  
MANNITOL  
MEGLUMINE  
POVIDONE K30  
SODIUM HYDROXIDE  
SODIUM STEARYL FUMARATE  
Product Characteristics
Color WHITE (white or off white to yellowish) Score no score
Shape CAPSULE Size 13mm
Flavor Imprint Code 1159
Contains     
Packaging
# Item Code Package Description
1 NDC:13668-159-30 30 TABLET in 1 BOTTLE
2 NDC:13668-159-01 100 TABLET in 1 BOTTLE
3 NDC:13668-159-74 100 TABLET in 1 CARTON
4 NDC:13668-159-72 30 TABLET in 1 CARTON
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA201192 02/25/2014
TELMISARTAN AND HYDROCHLORTHIAZIDE 
telmisartan and hydrochlorthiazide tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:13668-160
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
TELMISARTAN (TELMISARTAN) TELMISARTAN 80 mg
HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) HYDROCHLOROTHIAZIDE 12.5 mg
Inactive Ingredients
Ingredient Name Strength
FERRIC OXIDE RED  
HYPROMELLOSE 2910 (3 MPA.S)  
LACTOSE MONOHYDRATE  
MANNITOL  
MEGLUMINE  
POVIDONE K30  
SODIUM HYDROXIDE  
SODIUM STEARYL FUMARATE  
Product Characteristics
Color WHITE (White or off-white to yellowish) Score no score
Shape CAPSULE Size 17mm
Flavor Imprint Code 1160
Contains     
Packaging
# Item Code Package Description
1 NDC:13668-160-30 30 TABLET in 1 BOTTLE
2 NDC:13668-160-01 100 TABLET in 1 BOTTLE
3 NDC:13668-160-74 100 TABLET in 1 CARTON
4 NDC:13668-160-72 30 TABLET in 1 CARTON
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA201192 02/25/2014
TELMISARTAN AND HYDROCHLORTHIAZIDE 
telmisartan and hydrochlorthiazide tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:13668-161
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
TELMISARTAN (TELMISARTAN) TELMISARTAN 80 mg
HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) HYDROCHLOROTHIAZIDE 25 mg
Inactive Ingredients
Ingredient Name Strength
FERRIC OXIDE YELLOW  
HYPROMELLOSE 2910 (3 MPA.S)  
LACTOSE MONOHYDRATE  
MANNITOL  
MEGLUMINE  
POVIDONE K30  
SODIUM HYDROXIDE  
SODIUM STEARYL FUMARATE  
Product Characteristics
Color WHITE (White or off-white to yellowish) Score no score
Shape CAPSULE Size 17mm
Flavor Imprint Code 1161
Contains     
Packaging
# Item Code Package Description
1 NDC:13668-161-74 100 TABLET in 1 CARTON
2 NDC:13668-161-01 100 TABLET in 1 BOTTLE
3 NDC:13668-161-72 30 TABLET in 1 CARTON
4 NDC:13668-161-30 30 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA201192 02/25/2014
Labeler - TORRENT PHARMACEUTICALS LIMITED (916488547)
Registrant - Torrent Pharma, Inc. (790033935)
Establishment
Name Address ID/FEI Operations
TORRENT PHARMACEUTICALS LIMITED 916488547 MANUFACTURE(13668-159, 13668-160, 13668-161)
Revised: 04/2017   TORRENT PHARMACEUTICALS LIMITED

Dosing Adult

Hypertension: Oral:

Replacement therapy: Combination product can be substituted for individual titrated agents.

Initiation of combination therapy when monotherapy has failed to achieve desired effects:

Patients currently on telmisartan monotherapy: Initial dose if blood pressure is not currently controlled on telmisartan 80 mg monotherapy: Telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily; manufacturer labeling suggests that dose may be titrated up to telmisartan 160 mg/hydrochlorothiazide 25 mg once daily if blood pressure remains uncontrolled after 2 to 4 weeks of therapy; however, in mild to moderate hypertension, doses of telmisartan >80 mg were not associated with a greater reduction in blood pressure (Smith 2000).

Patients currently on hydrochlorothiazide monotherapy: Initial dose if blood pressure is not currently controlled on hydrochlorothiazide 25 mg once daily monotherapy or patients who experience hypokalemia while on hydrochlorothiazide 25 mg monotherapy: Telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily; manufacturer labeling suggests that dose may be titrated up to telmisartan 160 mg/hydrochlorothiazide 25 mg once daily if blood pressure remains uncontrolled after 2 to 4 weeks of therapy; however, in mild to moderate hypertension, doses of telmisartan >80 mg were not associated with a greater reduction in blood pressure (Smith 2000).

Dosing Renal Impairment

CrCl >30 mL/minute: No dosage adjustment necessary.

CrCl ≤30 mL/minute: Not recommended.

Test Interactions

See individual agents.

ALERT U.S. Boxed Warning

Fetal toxicity:

Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.

Pregnancy Risk Factor D Pregnancy Considerations

[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected. Also see individual agents.

(web3)